#Harpoon therapeutics download#
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
#Harpoon therapeutics plus#
In terms of the Zacks Industry Rank, Medical - Drugs is currently in the bottom 19% of the 250 plus Zacks industries. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. The current consensus EPS estimate is -$0.44 on $6.8 million in revenues for the coming quarter and -$1.87 on $27.15 million in revenues for the current fiscal year. It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. So, the shares are expected to perform in line with the market in the near future. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.Īhead of this earnings release, the estimate revisions trend for Harpoon Therapeutics, Inc. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.Įmpirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? What's Next for Harpoon Therapeutics, Inc. Shares have added about 35.5% since the beginning of the year versus the S&P 500's gain of 11%. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. The company has topped consensus revenue estimates two times over the last four quarters. This compares to year-ago revenues of $3.3 million.
Harpoon Therapeutics, Inc.Which belongs to the Zacks Medical - Drugs industry, posted revenues of $9.01 million for the quarter ended March 2021, surpassing the Zacks Consensus Estimate by 32.50%. Over the last four quarters, the company has surpassed consensus EPS estimates three times. A quarter ago, it was expected that this company would post a loss of $0.58 per share when it actually produced a loss of $0.45, delivering a surprise of 22.41%. This quarterly report represents an earnings surprise of 13.95%.
These figures are adjusted for non-recurring items. This compares to loss of $0.51 per share a year ago. The Investor Relations website contains information about Harpoon Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts. (HARP) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.43.
0 kommentar(er)
